Company profile for Recludix Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is advancing another...
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom-generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. The company is advancing another program with an undisclosed non-STAT SH2 domain target that also plays a significant role in both cancer and autoimmune diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3525 John Hopkins Court, Suite 150 San Diego, CA 92121
Telephone
Telephone
+1 8582585445
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/03/3179171/0/en/Recludix-Pharma-to-Present-at-Two-Investor-Conferences-in-November.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/09/11/3148857/0/en/Recludix-Pharma-to-Present-at-the-Stifel-2025-Virtual-Immunology-and-Inflammation-Forum.html

GLOBENEWSWIRE
11 Sep 2025

https://www.globenewswire.com/news-release/2025/07/14/3114692/0/en/Recludix-Pharma-Announces-Strengthening-of-Leadership-Team-Including-Promotion-of-Dr-Brian-Hodous-to-Chief-Scientific-Officer.html

GLOBENEWSWIRE
14 Jul 2025

https://www.globenewswire.com/news-release/2025/06/02/3091698/0/en/Recludix-Pharma-Announces-Development-Candidate-Nomination-of-First-in-Class-Oral-STAT6-Inhibitor-for-Inflammatory-Diseases-and-Achievement-of-Significant-Milestone-Under-Collabora.html

GLOBENEWSWIRE
02 Jun 2025

https://www.globenewswire.com/news-release/2025/05/19/3083940/0/en/Recludix-Pharma-Presents-Data-Demonstrating-Potent-Efficacy-and-High-Selectivity-of-a-STAT6-Inhibitor-in-Preclinical-Asthma-Model.html

GLOBENEWSWIRE
19 May 2025

https://www.globenewswire.com/news-release/2025/05/07/3076387/0/en/Recludix-Pharma-Presents-Preclinical-Data-on-First-in-Class-BTK-SH2-Domain-Inhibitor-Demonstrating-Powerful-BTK-Inhibition-Exceptional-Selectivity-and-Encouraging-Efficacy-in-a-Mod.html

GLOBENEWSWIRE
07 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty